During the past decade, University of Campania "Luigi Vanvitelli" conducted 53 clinical trials. In the 10-year time frame, 53 clinical trials started and 7 clinical trials were completed, i.e. on average, 13.2% percent of trials that started reached the finish line to date. In the past 5 years, 35 clinical trials started and 7 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Campania "Luigi Vanvitelli"" #1 sponsor was "University of Campania "Luigi Vanvitelli"" with 26 trials, followed by "National Cancer Institute, Naples" with 5 trials sponsored, "Celgene" with 3 trials sponsored, "Amylyx Pharmaceuticals Inc." with 2 trials sponsored and "Eli Lilly and Company" with 2 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Campania "Luigi Vanvitelli"" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 2 trials as a collaborator, "Federico II University" with 2 trials as a collaborator, "Monaldi Hospital" with 2 trials as a collaborator, "University of Campania "Luigi Vanvitelli"" with 2 trials as a collaborator and "Associazione Medici Diabetologi (AMD)" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "University of Campania "Luigi Vanvitelli"" are "Breast Cancer" (3 trials), "Metastatic Colorectal Cancer" (3 trials), "Amyotrophic Lateral Sclerosis" (2 trials), "Atrial Fibrillation" (2 trials) and "Carcinoma" (2 trials). Many other conditions were trialed in "University of Campania "Luigi Vanvitelli"" in a lesser frequency.

Most popular intervention types in "University of Campania "Luigi Vanvitelli"" are "Drug" (33 trials), "Other" (11 trials), "Diagnostic Test" (8 trials), "Procedure" (8 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "paclitaxel" (3 trials), "AMX0035" (2 trials), "Cisplatin" (2 trials) and "Gemcitabine" (2 trials). Other intervention names were less common.

The vast majority of trials in "University of Campania "Luigi Vanvitelli"" are 48 trials for "All" genders and 17 trials for "Female" genders.

Currently, there are 25 active trials in "University of Campania "Luigi Vanvitelli"". 1 are not yet recruiting, 16 are recruiting, 7 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 23 completed trials in University of Campania "Luigi Vanvitelli", undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in University of Campania "Luigi Vanvitelli", 0 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 8 trials that are defined as “Not Applicable".

University of Campania "Luigi Vanvitelli" has several departments that took part in Clinical trials: "Department of Geriatrics and Metabolic Diseases" - 6 trials, "Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli"" - 2 trials, "Dott. Fortunato Ciardiello,Cattedra Oncologia Medica" - 3 trials, "Università degli Studi della Campania Luigi Vanvitelli; Divsione Di Oncologia Medica" - 2 trials, "Università degli studi della Campania Luigi Vanvitelli; Dip.Ass Int Med Int-I Clinica Neurologica" - 2 trials